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Introduction
Human monocytes belong to the mononuclear 
phagocytes and play an important role in antigen 
non-specific and antigen-specific immune responses 
against bacteria, viruses, parasites and tumour cells. 
Peripheral blood monocytes originate in the bone 
marrow from pluripotent stem cells which give rise 
to committed colony forming unit-granulocyte/mac- 
rophage precursors (CFU-GM) that differentiate into 
promonocytes, monoblasts and monocytes. These 
monocytes leave the bone marrow and enter the cir­
culation, where they remain for approximately three 
days (Johnston, 1988). Peripheral blood monocytes 
form a heterogeneous population with regard to cell 
size, density, morphology, phenotype and function 
(Figdor et al., 1986). Subsequently, they enter the tis­
sues and differentiate into tissue-specific macro­
phages such as Kiippfer cells, histiocytes, alveolar 
macrophages, microglial cells and osteoclasts, under 
the influence of factors produced in the local en­
vironment.
Monocytes express receptors for IL4 and respond 
to this Th2 cytokine with dramatic changes in mor­
phology, phenotype and function. Recently, we 
described a novel cytokine, interleukin-13, and 
characterized its biological activities (McKenzie et a l, 
1993). IL13 is a protein consisting of 132 aa and has 
a M W  of s 10 kDa. It turns out that IL13 affects hu­
man monocytes in a similar way as does IL4 (de Waal 
Malefyt el al., 1993), and there is evidence that IL4R 
and IL13R may share a common component which 
is involved in signal transduction (Zurawski et a l, 
1993). In this paper, we will review the activities of 
IL4 toward monocytes and compare them with those 
of IL13.
Effects of IL4 and IL13 on the differentiation of 
monocytes
Although the effects of IL4 on haematopoiesis are 
beyond the scope of this communication, some com­
ments could be made on the effects of IL4 on the 
differentiation of myeloid cells. IL4 alone has no 
growth factor activity, but it significantly enhances 
the growth of granulocyte progenitors from CD34+ 
cells or bone marrow from 5-FU-treated mice when 
IL3, GM-CSF or G-CSF is present (Rennick et al., 
1987; Broxmeyer et al., 1988). However, IL4 has also 
been shown to inhibit the growth of macrophage pro­
genitors in human and mouse bone marrow cultured 
with M-CSF or GM-CSF and inhibited myelopoie- 
sis in the long-term Dexter type of in vitro cultures 
(Jansen et al., 1989; Rennick et al., 1992). This could 
be explained by the fact that IL4 induces the differen­
tiation of the progenitors into macrophages which 
are end stage cells that generally do not proliferate. 
IFNy has been shown to stimulate CFU-M from 
CD34+ HLA-DR+ bone marrow progenitors when 
IL3, GM-CSF or G-CSF was present, and to inhibit 
CFU-G in the presence of G-CSF (Snoeck et al., 
1993). IL4 antagonized this activity of IFNy and 
reversed both the suppression of CFU-G and the en­
hancement of CFU-M. Antagonistic activities of IL4 
and IFNy are also observed on cytokine production 
and on expression of Fc^R by mature monocytes (see 
below).
IL4 and IL13 induce dramatic changes in the mor­
phology of peripheral blood monocytes. Monocytes 
cultured in the presence of IL4 or IL13 form long 
cytoplasmic protrusions, have a dendritic appearance 
and adhere strongly to the substrate. Clumping of 
cells through homotypic interactions can also be ob-
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served (te Velde et a l, 1988; McKenzie et a l, 1993). 
IL4 or IL13 downregulates the expression of CD14 
and FcyR and upregulates the expression of class II 
M H C  antigens on monocytes. Based on their mor­
phology and phenotype, these cells resemble dendritic 
cells which also express high levels of class II M H C  
antigens but don't express FcyR and CD 14. 
However, dendritic cells express CD1 antigens which 
are not induced by IL4 or IL13 on monocytes and 
appear to be better antigen-presenting cells (Stein- 
man, 1991).
Cytokine production by monocytes is inhibited by 
IL4 and IL13
Human monocytes and mouse macrophages 
produce large amounts of a number of cytokines, in­
cluding IL10, following activation by LPS (de Waal 
Malefyt et a i 1991; Fiorentino et a l, 1991). En­
dogenously produced IL10 has autoregulatory effects 
on the production of cytokines by monocytes and in­
hibits the secretion of IL1, IL 6 , IL 8 , TNFa, GM- 
CSF, G-CSF and IL10 itself. Neutralization of this 
endogenously produced IL10 by a specific mAb 
results in enhanced production of cytokines by LPS- 
activated monocytes (de Waal Malefyt et aL, 1991). 
Under these conditions, IL4 and IL13 strongly in­
hibit the production of ILloc, IL ip , IL 6, IL 8, IL10, 
TNFoc, GM-CSF, G-CSF and M IP la  (te Velde et a l, 
1990b; Hart et a l3 1989; de W aal Malefyt et a l, 
1993; Minty et a l , 1993). Downregulation of these 
cytokines has been shown to occur at the m RN A  
level. IL4, IL13 and IL10 also inhibit the production 
of IL12 p35, IL12 p40 and IFNa (de W aal Malefyt 
et a l, 1993; Doherty et al., 1993). In addition, IL4 
has been shown to downregulate the production of 
MIP-ip (Ziegler et a l, 1991) and platelet-derived 
growth factor (PDGF) (S. Breitt, pers. comm.) by 
monocytes. The inhibitory effect of IL4 on the 
production of IL1 and TNFa has been demonstrat­
ed on human peripheral blood monocytes, human al­
veolar macrophages, human peritoneal macrophages 
and murine macrophages (Sone et a l, 1992 ; Hart et 
a l, 1991). Furthermore, IL4 inhibited cytokine 
production by monocytes activated by IL1, TNFa or 
IFNy (Lee et a l , 1990; Vellenga et a l, 1991). 
However, IL4 and IL13 do not inhibit the produc­
tion of all cytokines. Both IL4 and IL13 enhance the 
production of IL1 receptor antagonist by LPS- 
activated monocytes (Fenton et a l,  1992; Orino et 
a l, 1992; Wong et a l, 1993; de Waal Malefyt, 1993). 
Taken together, these data indicate that IL4 has an­
tiinflammatory activities through the inhibition of 
proinflammatory cytokine production and enhance­
ment of IL lra  production, a cytokine which itself 
possesses antiinflammatory activities.
IL4 and IL13 modulate expression of Fc receptors
The expression of Fc receptors by monocytes is 
strongly influenced by cytokines. IL4 and IL 13 in­
duce the expression of the low affinity Fc receptor 
for IgE (FceRII, CD23) on the cell surface and IL4 
has been shown to induce the release of soluble CD23 
(te Velde et a l, 1990c; Vercelli et a l ,  1988; McKen­
zie et a l, 1993). This enhanced expression of CD23 
may be important in allergy, since atopic patients 
have enhanced Fc&R-mediated cytotoxic activity 
(Melewiicz et a l, 1981). Multiple cytokines are in­
volved in regulation of FcyR expression, IFNy and 
IL10 enhance the expression of FcyRI (CD64), 
whereas TGFp upregulates the expression of FcyRI 
(CD16) (te Velde et a l, 1990a, 1992; Wong et a l, 
1991). IL4 and IL  13 downregulate the constitutive 
expression of all three FcyR: CD64, CD32 and CD 16 
(de Waal Malefyt et a l, 1993). Addition of combi­
nations of these cytokines showed that IL10 could 
prevent the IL4~ or IL13-induced downregulation of 
CD16, CD32 and CD64, whereas IFNy could par­
tially rescue the IL4- or IL13-induced downregula­
tion of CD64, but not that of CD32 and CD 16 (de 
Waal Malefyt et a l, 1993). In  addition, IL4 inhibit­
ed the TGF(3-induced expression of CD 16 (Wong et 
a l, 1991). FcyRI expression has been correlated with 
A D C C  activity of monocytes (Tripathi et a l, 1991). 
The spontaneous ADCC  activity of monocytes is en­
hanced by IFNy or IL10 and inhibited by IL4 or IL13 
(te Velde et a l, 1990a; te Velde et a l, 1992). 
However, IL4 and IL13 strongly inhibited the IFNy 
or IL10~induced A D C C  activity despite the fact that 
CD64 expression was not downregulated, indicating 
that besides CD64 expression, other mechanisms 
must play a role in the IL4- and IL1.3-induced inhi­
bition of monocyte cytotoxicity (de Waal Malefyt et 
a l, 1993).
IL4 inhibits production of NO and killing of 
intracellular parasites
Monocytes and macrophages are hosts for a num­
ber of intracellular parasites, including schistosoma, 
toxoplasma and leishmania species. Activation of 
macrophages by IFNy leads to killing of these in­
tracellular parasites via production of toxic nitrogen 
oxide metabolites (James et a l, 1989). IL4 is able to 
inhibit the killing of these intracellular parasites by 
blocking NO production. IL10 and TGF(3 share this 
activity with IL4 and combinations of these factors 
are synergistic (Oswald et a l ,  1992a). The 
ILlO-induced inhibition of NO production and para­
site killing is mediated through the downregulation 
of TNFa production by the monocyte, which acts as 
a cofactor for the IFNy-induced macrophage activa­
tion (Oswald et a l , 1992b). Additional mechanisms
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seem to play a role in the IL4-mediated suppression 
of NO production and parasite killing. However, IL4 
and IL10 inhibit not only intracellular parasites by 
this mechanism, but also other organisms, like Can­
dida albicans and Salmonella typhimurium (Cenci et 
a i, 1993 ; al-Ramadi et a i , 1992). IL13 and IL4 also 
inhibited the production of NO by macrophages 
established from bone marrow by cultures with 
GM-CSF but not from macrophages grown in 
M-CSF (Doherty et al., 1993). This corresponded to 
an enhanced survival of Leishmania major in the 
IL13- or IL4-treated GM-CSF cultured macrophages, 
but not in the IL13 or IL4-treated M-CSF cultured 
macrophages. IL4 has also been shown to inhibit the 
IFNy-induced production of reactive oxygen radicals 
(0 ‘ , H 20 2) (Abramson et a ls 1990; Bhaskaran et 
a i, 1992). These mechanisms, together with the in­
hibited production of TNFa, IL1 and IL6, may also 
explain the IL4-mediated inhibition of IFNy- 
activated monocytes to kill tumour cells (te Velde et 
al., 1988).
Concluding remarks
IL4 and IL13 have dramatic effects on monocyte 
morphology, phenotype and function. Both 
cytokines change the morphology of monocytes, in­
hibit production of pro-inflammatory cytokines, in­
hibit the expression of FcyR and inhibit the 
production of NO and 0~ which diminishes killing 
of intra- and extracellular pathogens (de Waal 
Malefyt et al., 1993; Doherty et a l, 1993). In addi­
tion, IL4 and IL13 inhibit the expression of CD 14, 
the receptor for the LPS/LPS binding protein com­
plex and of CD13 (aminopeptidase N), a cell surface 
marker with enzymatic activity (Van Hal et aL} 1992). 
However, IL4 and IL13 also have stimulatory activi­
ties toward monocytes. IL4 and IL13 enhance class
II M HC expression on monocytes, which may be 
related to an enhanced capacity to present antigen. 
This has been demonstrated for protein antigens in 
the mouse and alloresponses in humans (te Velde et 
al., 1988; Zlotnik et a l, 1987). In addition, IL4 and 
IL13 induce expression of CD23 and enhance the ex­
pression of C D llb , C D llc , CD18, CD29 and CD49e 
(FNR) (de Waal Malefyt et al., 1993). These (31 and 
P2 integrins play an important role in cell-cell inter­
actions and interactions with the extracellular matrix 
(Hogg, 1989). The enhanced expression of these an­
tigens may play a role in the IL4- and IL13-induced 
changes in adhesion and morphology. Finally, IL4 
has been shown to activate 15-lipoxygenase, an en­
zyme involved in the oxidation of low density 
lipoprotein (LDL) to its atherogenic form in mono­
cytes (Conrad et a l, 1992). This activation could be 
inhibited by IFNy. Therefore, IL4 could play a role 
in the pathogenesis of atherosclerosis and the forma­
tion of foam cells.
IL13 shares many of the known activities of IL4 
on monocytes (de Waal Malefyt et a l, 1993 ; Doherty 
et a l, 1993). Both cytokines inhibited monocyte func­
tions which are related to cellular (Thl) immune 
responses. In addition, it has been shown that IL13, 
like IL4, induced human B-cell proliferation, B-cell 
differentiation and IgG4 and IgE production (Pun- 
nonen et a l, 1993). IL13, like IL4, also induced the 
transcription of the germline t locus and acts as a 
switch factor (Cocks et a l, 1993). These results may 
partially be explained by the finding that IL4R and 
IL13R share a common subunit which is involved in 
signal transduction (Zurawski et al., 1993). IL4 and 
IL13 are predominantly products of Th2 cells, 
although human Thl cells are able to produce IL13 
(de Waal Malefyt and H. Yssel, in prep.). IL13 
production is more abundantly and longer produced 
by T-cell clones than IL4. However, in contrast to 
IL4, IL13 is not active as T-cell growth factor (de 
Waal Malefyt and H. Yssel, in prep.). These data in­
dicate that IL4 and IL 13 may have similar and unique 
roles in regulation of immune responses despite the 
fact that both IL4 and IL13 have similar effects on 
monocyte physiology and function.
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The anti-tumour and proinflammatory actions of IL4
R.I. Tepper 
Massachusetts General Hospital Harvard Medical School, Boston, MA (USA)
Introduction
As a highly pleiotropic cytokine, IL4 has been 
shown to stimulate proliferative or differentiative 
responses in numerous cell types, not only in the lym­
phoid and non-lymphoid haematopoietic lineage, but 
also in cells of non-haematopoietic origin, such as 
endothelial cells. In terms of anti-tumour activity, 
IL4 has been shown to induce a potent cytotoxic 
response against tumours which is likely mediated by 
several host effector cell types. Both lymphoid- 
independent inflammatory cell mechanisms and 
CTL-mediated anti-tumour responses have been 
reported as a result of IL4 expression. This report 
attempts to summarize the biologic basis for the anti­
tumour mechanisms initiated by IL4, defining exist­
ing controversies with regard to these mechanisms
and offering approaches for future research investi­
gations and clinical applications of this important ac­
tion of IL4.
The localized anti-tumour action of IL4 in vivo
The action of IL4 (or other cytokines) locally at 
the inoculation site of transplantable tumours has 
been readily assessed by a “ tumour-cytokine trans­
plantation assay” (Tepper, 1992), in which a constit- 
utively acting gene for IL4 is transfected directly into 
the tumour cells, or alternatively, by mixing tumour 
cells with an IL4-producing cell type prior to injec­
tion. Using such an assay, we have demonstrated that 
the expression of an activated murine IL4 gene lo­
cally results in a potent anti-tumour effect, with com-
